Your browser doesn't support javascript.
loading
CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.
Sutton, Linda M; Geradts, Joseph; Hamilton, Erika P; Havlin, Kathleen A; Kimmick, Gretchen G; Marcom, P Kelly; Spector, Neil L; Watson, Melanie; Rabin, Daniel U; Bruno, Theodore O; Noe, Amanda; Miller, Stacy; Subramaniam, Chitra; Layton, Sherry; Grichnik, Katherine.
Afiliação
  • Sutton LM; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Geradts J; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Hamilton EP; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Havlin KA; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Kimmick GG; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Marcom PK; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Spector NL; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Watson M; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Rabin DU; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Bruno TO; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Noe A; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Miller S; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Subramaniam C; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Layton S; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
  • Grichnik K; From Department of Medicine, Duke School of Medicine and Health System, and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee; The France Foundation, Old Lyme, Connecticut; Duke Medicine, Center F
J Natl Compr Canc Netw ; 13(8): 1005-11, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26285246
ABSTRACT
CHAMBER was a regional educational initiative for providers of care to patients with HER2+ breast cancer. The study goals were to (1) enhance testing for HER2/neu overexpression in patients with invasive breast cancer; (2) increase the appropriate use of targeted therapy for patients with HER2+ breast cancer; and (3) enhance patients' coping ability. This Performance Improvement Continuing Medical Education (PI-CME) initiative included clinical practice assessment, educational activities, and reassessment. Chart review revealed a high rate of HER2 testing (98%) before and after education. Targeted therapy for patients with HER2+ breast cancer declined after the program (from 96% to 61%), perhaps attributable to an increase in awareness of medical reasons to avoid use of targeted therapy. Assessment for patients' emotional coping ability increased after education (from 55% to 76%; P=.01). Rates of testing for HER2 amplification and assessment of emotional well-being after education were consistent with ASCO Quality Oncology Practice Initiative benchmark values. Documentation of actions to address emotional problems remained an area for improvement.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Pessoal de Saúde / Educação Médica Continuada / Melhoria de Qualidade Limite: Female / Humans Idioma: En Revista: J Natl Compr Canc Netw Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Pessoal de Saúde / Educação Médica Continuada / Melhoria de Qualidade Limite: Female / Humans Idioma: En Revista: J Natl Compr Canc Netw Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article